BRIEF—Etcembly appoints Scott Cuthill as chief business officer

Etcembly today announced the appointment of Scott Cuthill as chief business officer (CBO). The Oxford, UK-based based company is harnessing the power of the adaptive immune system to transform the precision, scale and speed of development of TCR immunotherapies.

Etcembly’s chief executive and co-founder Dr Michelle Teng said: “On behalf of the Etcembly team, I am delighted to welcome Scott as our CBO. Scott brings a wealth of business development expertise from an impressive career spanning both global Pharma and Biotech. Scott’s leadership of this strategically important function will be key to maximizing the full potential of EMLy the world’s largest machine learning database of T cell repertoires. Paired with our unmatched immunology expertise, we will deliver safe and potent TCR immunotherapies through rapid computer-driven engineering.”

Dr Cuthill has over 25 years’ experience in the pharma and biotech industry, gained initially in a variety of R&D roles at Roche and OSI Pharmaceuticals in the UK, in oncology and viral diseases. He has considerable business development experience, having successfully led both in and out-licensing deals for assets ranging from early-stage platform technologies to marketed products. Dr Cuthill has held senior business development roles most recently at Finland-based Valo Therapeutics, Chroma Therapeutics, and Ipsen Biopharma.